Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.

de Coaña YP, Wolodarski M, Poschke I, Yoshimoto Y, Yang Y, Nyström M, Edbäck U, Brage SE, Lundqvist A, Masucci GV, Hansson J, Kiessling R.

Oncotarget. 2017 Mar 28;8(13):21539-21553. doi: 10.18632/oncotarget.15368.

2.

Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma.

Poschke I, Faryna M, Bergmann F, Flossdorf M, Lauenstein C, Hermes J, Hinz U, Hank T, Ehrenberg R, Volkmar M, Loewer M, Glimm H, Hackert T, Sprick MR, Höfer T, Trumpp A, Halama N, Hassel JC, Strobel O, Büchler M, Sahin U, Offringa R.

Oncoimmunology. 2016 Oct 7;5(12):e1240859. doi: 10.1080/2162402X.2016.1240859. eCollection 2016.

3.

Next-generation TCR sequencing - a tool to understand T-cell infiltration in human cancers.

Poschke I, Flossdorf M, Offringa R.

J Pathol. 2016 Dec;240(4):384-386. doi: 10.1002/path.4800. Epub 2016 Oct 21.

PMID:
27569598
4.

Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer.

Miyan M, Schmidt-Mende J, Kiessling R, Poschke I, de Boniface J.

J Transl Med. 2016 Jul 29;14(1):227. doi: 10.1186/s12967-016-0983-9.

5.

Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis.

Andersson E, Poschke I, Villabona L, Carlson JW, Lundqvist A, Kiessling R, Seliger B, Masucci GV.

Oncoimmunology. 2015 Jul 25;5(1):e1052213. eCollection 2016.

6.

A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes.

Khandelwal N, Breinig M, Speck T, Michels T, Kreutzer C, Sorrentino A, Sharma AK, Umansky L, Conrad H, Poschke I, Offringa R, König R, Bernhard H, Machlenkin A, Boutros M, Beckhove P.

EMBO Mol Med. 2015 Apr;7(4):450-63. doi: 10.15252/emmm.201404414.

7.

A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma.

Poschke I, Lövgren T, Adamson L, Nyström M, Andersson E, Hansson J, Tell R, Masucci GV, Kiessling R.

Cancer Immunol Immunother. 2014 Oct;63(10):1061-71. doi: 10.1007/s00262-014-1575-2. Epub 2014 Jul 4.

PMID:
24993563
8.

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production.

Pico de Coaña Y, Poschke I, Gentilcore G, Mao Y, Nyström M, Hansson J, Masucci GV, Kiessling R.

Cancer Immunol Res. 2013 Sep;1(3):158-62. doi: 10.1158/2326-6066.CIR-13-0016. Epub 2013 Aug 2. Erratum in: Cancer Immunol Res. 2013 Dec;1(6):438.

9.

Prevailing role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer.

Hartmann N, Giese NA, Giese T, Poschke I, Offringa R, Werner J, Ryschich E.

Clin Cancer Res. 2014 Jul 1;20(13):3422-33. doi: 10.1158/1078-0432.CCR-13-2972. Epub 2014 Apr 24.

10.

Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells.

Mao Y, Poschke I, Kiessling R.

J Intern Med. 2014 Aug;276(2):154-70. doi: 10.1111/joim.12229. Epub 2014 Mar 24. Review.

11.

Tumor-dependent increase of serum amino acid levels in breast cancer patients has diagnostic potential and correlates with molecular tumor subtypes.

Poschke I, Mao Y, Kiessling R, de Boniface J.

J Transl Med. 2013 Nov 16;11:290. doi: 10.1186/1479-5876-11-290.

12.

Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.

González FE, Ramírez M, Allerbring EB, Fasching N, Lundqvist A, Poschke I, Achour A, Salazar-Onfray F.

Immunobiology. 2014 Mar;219(3):189-97. doi: 10.1016/j.imbio.2013.10.002. Epub 2013 Oct 12.

PMID:
24192537
13.

Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms.

Mao Y, Poschke I, Wennerberg E, Pico de Coaña Y, Egyhazi Brage S, Schultz I, Hansson J, Masucci G, Lundqvist A, Kiessling R.

Cancer Res. 2013 Jul 1;73(13):3877-87. doi: 10.1158/0008-5472.CAN-12-4115. Epub 2013 Apr 30.

14.

Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients.

de Boniface J, Mao Y, Schmidt-Mende J, Kiessling R, Poschke I.

Oncoimmunology. 2012 Nov 1;1(8):1305-1312.

15.

On the armament and appearances of human myeloid-derived suppressor cells.

Poschke I, Kiessling R.

Clin Immunol. 2012 Sep;144(3):250-68. doi: 10.1016/j.clim.2012.06.003. Epub 2012 Jun 20. Review.

PMID:
22858650
16.

Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation.

Mougiakakos D, Jitschin R, von Bahr L, Poschke I, Gary R, Sundberg B, Gerbitz A, Ljungman P, Le Blanc K.

Leukemia. 2013 Feb;27(2):377-88. doi: 10.1038/leu.2012.215. Epub 2012 Jul 25.

PMID:
22828446
17.

Tumor-induced changes in the phenotype of blood-derived and tumor-associated T cells of early stage breast cancer patients.

Poschke I, De Boniface J, Mao Y, Kiessling R.

Int J Cancer. 2012 Oct 1;131(7):1611-20. doi: 10.1002/ijc.27410. Epub 2012 Jan 31.

18.

Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines.

Poschke I, Mao Y, Adamson L, Salazar-Onfray F, Masucci G, Kiessling R.

Cancer Immunol Immunother. 2012 Jun;61(6):827-38. doi: 10.1007/s00262-011-1143-y. Epub 2011 Nov 12.

PMID:
22080405
19.

Tumor-dependent down-regulation of the ζ-chain in T-cells is detectable in early breast cancer and correlates with immune cell function.

Boniface JD, Poschke I, Mao Y, Kiessling R.

Int J Cancer. 2012 Jul 1;131(1):129-39. doi: 10.1002/ijc.26355. Epub 2011 Aug 30.

20.

Camouflage and sabotage: tumor escape from the immune system.

Poschke I, Mougiakakos D, Kiessling R.

Cancer Immunol Immunother. 2011 Aug;60(8):1161-71. doi: 10.1007/s00262-011-1012-8. Epub 2011 Apr 6. Review.

PMID:
21626032
21.

T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2.

Mimura K, Ando T, Poschke I, Mougiakakos D, Johansson CC, Ichikawa J, Okita R, Nishimura MI, Handke D, Krug N, Choudhury A, Seliger B, Kiessling R.

Int J Cancer. 2011 Jan 15;128(2):390-401. doi: 10.1002/ijc.25613. Epub 2010 Oct 13.

22.

Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.

Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, Knutson KL, Bergh J, Lidbrink E, Kiessling R.

J Transl Med. 2010 Jun 7;8:53. doi: 10.1186/1479-5876-8-53.

23.

Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.

Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R.

Cancer Res. 2010 Jun 1;70(11):4335-45. doi: 10.1158/0008-5472.CAN-09-3767. Epub 2010 May 18.

24.

Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells.

Carlsten M, Norell H, Bryceson YT, Poschke I, Schedvins K, Ljunggren HG, Kiessling R, Malmberg KJ.

J Immunol. 2009 Oct 15;183(8):4921-30. doi: 10.4049/jimmunol.0901226.

25.

Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma.

Johansson CC, Egyházi S, Masucci G, Harlin H, Mougiakakos D, Poschke I, Nilsson B, Garberg L, Tuominen R, Linden D, Stolt MF, Hansson J, Kiessling R.

Cancer Immunol Immunother. 2009 Jul;58(7):1085-94. doi: 10.1007/s00262-008-0631-1. Epub 2008 Nov 28.

PMID:
19039588
26.

Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas.

Kruschinski A, Moosmann A, Poschke I, Norell H, Chmielewski M, Seliger B, Kiessling R, Blankenstein T, Abken H, Charo J.

Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17481-6. doi: 10.1073/pnas.0804788105. Epub 2008 Nov 5.

27.

Progress in vaccination against cancer-7: report of the meeting in Stockholm, September 10-11, 2007.

Kiessling R, De Geer A, Johansson C, Poschke I, Triulzi C, Vertuani S.

Cancer Immunol Immunother. 2008 Apr;57(4):593-9. Epub 2007 Nov 20. No abstract available.

PMID:
18026952
28.

The CD16- CD56(bright) NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56(dim) subset.

Harlin H, Hanson M, Johansson CC, Sakurai D, Poschke I, Norell H, Malmberg KJ, Kiessling R.

J Immunol. 2007 Oct 1;179(7):4513-9.

Supplemental Content

Loading ...
Support Center